 Connection
Nicholas Di bella to Humans
This is a "connection" page, showing publications Nicholas Di bella has written about Humans.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.040 |
|
|
|
-
Di Bella NJ, Bhowmik D, Bhor M, Yap M, Middlebrook B, Rembert D, Cain Z, Okoro T, Bolinder B, Patt D, Jabbour EJ. The Effectiveness of Tyrosine Kinase Inhibitors and Molecular Monitoring Patterns in Newly Diagnosed Patients With Chronic Myeloid Leukemia in the Community Setting. Clin Lymphoma Myeloma Leuk. 2015 Oct; 15(10):599-605.
Score: 0.011
-
Di Bella N, Taetle R, Kolibaba K, Boyd T, Raju R, Barrera D, Cochran EW, Dien PY, Lyons R, Schlegel PJ, Vukelja SJ, Boston J, Boehm KA, Wang Y, Asmar L. Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma. Blood. 2010 Jan 21; 115(3):475-80.
Score: 0.008
-
Di Bella N, Ravandi F. Purine analogue combinations for indolent lymphomas. Semin Hematol. 2006 Apr; 43(2 Suppl 2):S11-21.
Score: 0.006
-
Di Bella N, Reynolds C, Faragher D, Muscato J, Boehm KA, Asmar L. An open-label pilot study of pentostatin, mitoxantrone, and rituximab in patients with previously untreated, Stage III or IV, low-grade non-Hodgkin lymphoma. Cancer. 2005 Mar 01; 103(5):978-84.
Score: 0.005
-
Di Bella NJ, Khan MM, Dakhil SR, Logie KW, Marsland TA, Weinstein RE, Mirabel MY, Asmar L. Pegylated liposomal doxorubicin as single-agent treatment of low-grade non-Hodgkin's lymphoma: a phase II multicenter study. Clin Lymphoma. 2003 Mar; 3(4):235-40.
Score: 0.005
-
Reynolds C, Di Bella N, Lyons RM, Hyman W, Richards DA, Robbins GJ, Vellek M, Boehm KA, Zhan F, Asmar L. A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia. Invest New Drugs. 2012 Jun; 30(3):1232-40.
Score: 0.002
-
Venkatesh H, Di Bella N, Flynn TP, Vellek MJ, Boehm KA, Asmar L. Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma. Clin Lymphoma. 2004 Sep; 5(2):110-5.
Score: 0.001
-
Drapkin R, Di Bella NJ, Faragher DC, Harden E, Matei C, Hyman W, Mirabel M, Boehm KA, Asmar L. Results of a phase II multicenter trial of pentostatin and rituximab in patients with low grade B-cell non-Hodgkin's lymphoma: an effective and minimally toxic regimen. Clin Lymphoma. 2003 Dec; 4(3):169-75.
Score: 0.001
-
Di Bella NJ, Blom J, Slawson RG. Splenectomy and hematologic tolerance to irradiation in Hodgkin's disease. Radiology. 1973 Apr; 107(1):195-200.
Score: 0.001
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|